Angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been shown in numerous studies to be effective therapeutic approaches for patients with AS, significantly postponing the onset of renal failure in these individuals (Boeckhaus et al. 2022; Nozu et al. 2019; Yamamura et al. 2020; Zeng et al. 2023; Zhang et al. 2021). This evidence concerns the gene ACE and kidney failure.